Yale University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).
Yale University: 1,492 sponsored US clinical trials, 254 recruiting.
Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.
Top-decile sponsor footprint
Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,492 total, page 1 of 30
Abriendo Caminos: Engaging Latinos
NCT07529509
Colorectal Cancer Screening Outreach
NCT07345676
Evaluation of a Mobile App Program for Coping With Cancer
NCT06923501
Music for Pain and Dementia
NCT07602283
Effect of the Thrive AI Health App on Lifestyle Behaviors and Quality of Life
NCT07376655
Project STRONGER: Stepped Care for Opioid Use Disorder Treatment Engagement and Recovery
NCT07115030
Skin Color Matching in Head and Neck Reconstructive Surgery
NCT07431099
Continuous Positive Airway Pressure, Arousability and Links to Mechanisms in Obstructive Sleep Apnea
NCT07332442
Phase 2 Study of Apremilast in Women and Men With Alcohol Use Disorder
NCT07029529
Long Term Evaluation of Scapular-inserted Contraceptive Implants
NCT07201402
CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs
NCT07172256
Speech Motor Learning and Retention (Aim 3)
NCT06492252
Evaluation of the Clinical and Psychological Impact of Vitamin D Replacement in Adolescent Females at Risk for Polycystic Ovarian Syndrome (PCOS)
NCT04355572
Implementation Facilitation Pilot for Alcohol Use Disorder (AUD) in Alcohol-associated Liver Disease (ALD)
NCT07525258
PoRI Clinical Trial
NCT07407023
Integrating PrEP Decision Making Into Counseling in Sexual and Reproductive Health Clinics
NCT06684613
Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)
NCT07223983
Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
NCT07273838
Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients
NCT07224087
Evaluation of [18F]GATT-44 for Positron Emission Tomography Imaging of the GABA Transporter-1
NCT07457736
A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis
NCT07291180
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
NCT07282912
Aerobic Exercise and Obsessive-Compulsive Disorder Symptoms
NCT07103902
Life at 100.4: An Immersive Social Virtual Reality (VR) Education Tool for Adolescent and Young Adult Cancer Patients and Caregivers
NCT07224204
Digital Mindfulness for Young Adults With Type 1 Diabetes
NCT07062887
Investigation of Lymph Node Biology in Kidney Cancer
NCT07038733
Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing
NCT07281014
Iadademstat + SBRT With Atezo in ES-SCLC
NCT07113691
Home-based Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for IBS Pain
NCT06847360
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
NCT07040592
Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot Study
NCT07301216
Non-invasive Venous Pressure Estimation
NCT07226479
Project Women's Insomnia Sleep Health Equity Study (WISHES)
NCT06348082
Saci Nivo Rela for TNBC
NCT06963905
Luspatercept + Darbepoetin in MDS
NCT07096297
FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy
NCT06917313
RCT of Cervical Ripening Double Ballon Catheter Prior to Dilation and Evacuation.
NCT07200115
Identification of Brain Injury Using Portable MRI
NCT07197918
Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma
NCT07048457
Shared Decision Making to Treat Or Prevent (STOP) HIV in Justice Populations (R33)
NCT07223398
New Mechanisms of Obesity
NCT06768827
Neural Mechanisms of the Social Brain
NCT07457567
Parent-Based Treatment for Adolescent Anxiety
NCT07219992
Hyperfractionated Dual Equivalent Fractionated Radiation Therapy
NCT06898905
SORE Study: Sitz Baths After Urogynecologic Reconstruction
NCT07215780
Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC
NCT07066189
Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography Images
NCT07228429
A Trial of Varenicline for E-cigarette Cessation
NCT07040566
Subcortical Arousal in Perceptual Awareness
NCT06934356
A Trial Comparing High-Flow Nasal Cannula Versus Noninvasive Ventilation on Reintubation and Post-Extubation Respiratory Failure in High-Risk Patients With Systolic Heart Failure
NCT06671015
What is open in the Yale University pipeline
254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).
Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).
Top condition: Opioid Use Disorder (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yale University: open-pipeline peers nationwide
Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,492 trials (± recruiting share)
- Washington University School of Medicine · 1,502 trials · 14% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 17% open enrollment (± trial volume)
- NYU Langone Health · 17% recruiting · 1,164 trials
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
Related
What to do with this Yale University page
1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.
- 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Yale University pipeline card: 1,492 registered trials from official public datasets.Report a data error.